How do you manage an atrial septal defect (ASD)?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: October 31, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Management of Atrial Septal Defects

Closure of an atrial septal defect (ASD) is indicated for patients with right atrial and right ventricular enlargement with or without symptoms to prevent long-term complications. 1, 2

Types of ASDs and Closure Approaches

  • Secundum ASDs (most common type) can be closed percutaneously with a device when anatomically suitable 1, 2, 3
  • Sinus venosus, coronary sinus, and primum ASDs require surgical closure rather than percutaneous approaches 1, 4
  • Small ASDs (<5 mm) without evidence of RV volume overload generally do not require closure unless associated with paradoxical embolism 1, 2

Indications for ASD Closure

  • Presence of right atrial and right ventricular enlargement (with or without symptoms) 1
  • Prevention of long-term complications including:
    • Atrial arrhythmias
    • Reduced exercise tolerance
    • Hemodynamically significant tricuspid regurgitation
    • Right-to-left shunting and embolism during pregnancy
    • Congestive heart failure
    • Pulmonary vascular disease (develops in 5-10% of affected individuals, mainly females) 1
  • Paradoxical embolism 1, 2
  • Documented orthodeoxia-platypnea (positional hypoxemia) 1

Contraindications to Closure

  • Severe irreversible pulmonary arterial hypertension (PAH) with no evidence of left-to-right shunt (Eisenmenger physiology) 1, 4

Percutaneous Device Closure

  • Preferred for secundum ASDs when anatomically suitable 2, 3
  • Benefits over surgical closure include:
    • Shorter hospital stay
    • Avoidance of sternotomy
    • Lower cost
    • More rapid recovery 3, 5
  • FDA-approved devices include:
    • Amplatzer® Septal Occluder (most commonly used)
    • Amplatzer® Cribriform device (for fenestrated ASDs)
    • Gore HELEX® device (useful for small to medium-sized defects) 3, 6

Surgical Closure

  • Indicated for:
    • Sinus venosus, coronary sinus, or primum ASDs 1, 4
    • Secundum ASDs when concomitant surgical repair/replacement of tricuspid valve is needed 1
    • When anatomy precludes use of percutaneous device 1
  • Should be performed by surgeons with training and expertise in congenital heart disease 1, 4
  • Surgical approaches include:
    • Pericardial patch closure
    • Direct suture closure 1, 7
  • Concomitant Maze procedure may be considered for intermittent or chronic atrial tachyarrhythmias 1

Special Considerations

  • Patients with pulmonary hypertension but with net left-to-right shunting may be considered for closure if:
    • Pulmonary artery pressure is less than two-thirds systemic levels
    • Pulmonary vascular resistance is less than two-thirds systemic vascular resistance
    • Patient is responsive to pulmonary vasodilator therapy or test occlusion of the defect 1
  • Patients with atrial arrhythmias and ASD should undergo both arrhythmia management and ASD closure 1
  • Earlier closure (before age 25) results in better long-term outcomes and lower incidence of atrial arrhythmias 1

Post-Procedure Management

  • Monitor for early postoperative symptoms of undue fever, fatigue, vomiting, chest pain, or abdominal pain which may indicate postpericardiotomy syndrome with tamponade 1, 2
  • Annual clinical follow-up is recommended for patients with:
    • Pulmonary arterial hypertension
    • Atrial arrhythmias
    • Right or left ventricular dysfunction
    • Coexisting valvular or other cardiac lesions 1
  • Evaluation for possible device migration, erosion, or other complications 3 months to 1 year after device closure and periodically thereafter 1, 5
  • Monitor for potential late complications after device closure including:
    • Device thrombosis
    • Cardiac erosion
    • Atrial arrhythmias (most common)
    • Nickel allergy
    • Cardiac conduction abnormalities
    • Valvular damage
    • Device endocarditis 5, 8

Outcomes

  • Early mortality is approximately 1% in the absence of PAH or other major comorbidities 1, 2
  • Long-term follow-up shows excellent results with decrease or resolution of preoperative symptoms 1, 8
  • Closure is associated with improvement in functional class, right ventricular pressure, volumes, and dimensions 2, 8

References

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Guideline

Management of Secundum Atrial Septal Defect (ASD)

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Guideline

Management of Sinus Venosus Atrial Septal Defect

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Research

When and how should atrial septal defects be closed in adults?

The Journal of invasive cardiology, 2009

Research

Surgical Treatment of Atrial Septal Defects.

Reviews in cardiovascular medicine, 2024

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.